SAGE Therapeutics (SAGE) 'Hits It Out of the Park' with SAGE-217 Data - Cowen

Sage Therapeutics to Provide Update on Key 2019 Initiatives at J.P. Morgan Healthcare Conference

Multi-franchise strategy ongoing in depression, neurology and neuropsychiatry

Commercial infrastructure build completed for ZULRESSO (brexanolone) injection ahead of March 19, 2019 target PDUFA date

Statistically significant results achieved in Phase 3 trial of SAGE-217 in postpartum depression

First patient dosed in second pivotal trial of SAGE-217 in major depressive disorder

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Chief Executive Officer,... More

Sage Therapeutics Announces SAGE-217 Meets Primary and Secondary Endpoints in Phase 3 Clinical Trial in Postpartum Depression

Statistically significant reduction observed in depressive symptoms compared to placebo in women with postpartum depression (PPD)

Well-tolerated with rapid onset of statistically significant effect (Day 3) through two weeks and maintained for four weeks after treatment

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported top-line results from the Phase 3 ROBIN Study. This study evaluated the effect of SAGE-217 30 mg on depressive symptoms in women with postpartum depression (PPD). After two weeks of outpatient... More

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics(NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on January 2, 2019, the Compensation Committee of Sages Board of Directors granted non-qualified stock options to purchase an aggregate of 15,000 shares of its common stock to five new employees under Sages 2016 Inducement Equity Plan.

The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee... More